The FDA just rewrote 20 years of women's medicine.

Months ago, the FDA quietly did something in women's medicine that should have made front-page news. It removed the black box warning from hormone replacement therapy.

If that sentence does not immediately mean something to you, let us translate. For more than two decades, every estrogen product prescribed to a menopausal woman in this country has carried the FDA's most severe form of warning label. A black-bordered box on the package insert telling women and their doctors that the medication could cause cancer, stroke, heart attack, and dementia. That warning shaped the medical conversation, the prescribing patterns, and most of all, the fear, of two entire generations of women.

It was wrong. The science has been solidly conclusive for years. The labeling is finally catching up.

What the FDA changed

The FDA's announcement cited the modern data that has been accumulating for years. Women who initiate HRT within ten years of menopause onset, generally before age 60, see a reduction in all-cause mortality and fractures. Up to a 50 percent reduction in cardiovascular disease risk. A 35 percent reduction in Alzheimer's risk. A 50 to 60 percent reduction in bone fractures.

That is not a marketing claim. That is the FDA citing the actual randomized trial data in their own announcement.

The labeled recommendation now is to start HRT within ten years of menopause onset or before age 60 for systemic therapy. This is the agency saying, formally and on the record, that hormone replacement therapy started in the right window, in the right woman, is one of the most powerful preventive protocols we have.

So how did we spend twenty-three years telling women the exact opposite?

The study that broke a generation of women’s medicine

The Women's Health Initiative was a National Institutes of Health study launched in the early 1990s to evaluate whether hormone therapy could prevent chronic disease in postmenopausal women. It enrolled over 16,000 women and randomized them to receive either hormone therapy or placebo.

Here is what almost no one talks about. The women in this study were not the women a thoughtful clinician would actually prescribe HRT to.

The average age of participants was 63. The typical menopausal woman starts hormone therapy in her early 50s, within a few years of her last period, when her own estrogen has only recently dropped. The WHI population was, on average, more than a decade past that window. Seventy-three percent of the women in the combined hormone arm had never taken HRT before.

The formulation was also not what modern protocols use. The WHI tested oral conjugated equine estrogens (Premarin, derived from the urine of pregnant horses), combined with medroxyprogesterone acetate, a synthetic progestin. Both were the dominant formulations in the 1990s, and neither is what a modern HRT protocol looks like.

When the trial was stopped early in 2002, the researchers reported an increased risk of breast cancer in the combined hormone arm. The hazard ratio was 1.26, right at the edge of statistical significance. In any other context, this would have been reported as a signal worth following up. It was treated, almost universally, as conclusive proof of harm.

The findings were then applied to all hormone therapy, of every formulation, route, and timing. Transdermal estradiol patches. Micronized progesterone. Women in their early 50s at the start of menopause. None of those had been studied. It did not matter.

And what almost no one mentioned, then or in the twenty years since, was the other arm of the same study. Women who received estrogen alone, without the synthetic progestin, actually had a lower risk of invasive breast cancer than the placebo group.

What good HRT actually looks like now

The clinical conversation about hormone replacement has moved on. Here is the version modern longevity-focused practices have been prescribing for years.

Bioidentical, not synthetic. Bioidentical hormones are structurally identical to what your body makes. Estradiol is bioidentical and is what we use. Conjugated equine estrogens are not. Micronized progesterone, which is structurally identical to your own, has a dramatically different risk profile from the synthetic progestin used in the WHI. The two should never have been discussed in the same sentence.

Transdermal, not oral. Estrogen taken by mouth is processed by the liver first, which increases clotting factors. Estradiol delivered through the skin bypasses that first pass and does not carry the same clotting signal. Modern protocols use transdermal estradiol as the default.

Early, not late. The window matters more than almost anything else. The FDA now says start within ten years of menopause onset or before age 60. The benefits compound when you start early. The risk profile shifts unfavorably when you start late. This is the single biggest reason the WHI results were misleading. The women studied were, on average, more than a decade past the window when this medication does its best work.

Individualized, not standardized. Dose, formulation, and timing should be tailored to your labs, your symptoms, your goals, and your risk factors. Modern HRT, done well, is not one-size-fits-all.

What this means if you are perimenopausal or menopausal right now

The simplest version: if you are within ten years of menopause, or before 60, and you have been told you cannot or should not take hormones, that conversation deserves to be reopened with a provider who understands the modern protocols.

You may not be a candidate. There are real contraindications, and they need to be evaluated individually. But the blanket assumption that hormones are off the table for any woman over 50 is wrong. It has always been wrong. And as of the FDA's own decision, it is now wrong according to the agency itself.

If you are in your 40s and starting to think about what perimenopause will look like for you, this is the time to find your providers. The window matters. The conversation is easier to start before you are in the middle of the symptoms.

This is the largest, most overdue correction in women's medicine in a generation. It is also the beginning of a longer conversation about how women's health has been studied, prescribed for, and talked about across an entire life cycle. Modern HRT, done properly, is a genuinely powerful part of what longevity medicine has to offer women. And now the conversation is finally allowed to be honest.